Scilex (SCLX) vs VivoSim Labs (VIVS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
VivoSim Labs is the larger company by market cap ($5.3 million vs $4.0 million), about 1.3 times the size. Scilex converts more of its revenue into profit, with a net margin of -1236.4% versus -10567.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SCLX | VIVS |
|---|---|---|
| Share price | $0.5658 | $0.2608 |
| Market cap | $3.98M | $5.29M |
| 1-day change | -12.95% | -10.53% |
| YTD return | -92.55% | — |
| 1-year return | -95.96% | — |
| 5-year return | -99.74% | — |
| Forward P/E | 0.78 | — |
| EPS (TTM) | $-49.70 | $-3.41 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $30.25M | $131.00K |
| Revenue growth (YoY) | -46.54% | -9.03% |
| Net income (latest FY) | $-374.05M | $-13.84M |
| Gross margin | 415.83% | 100.00% |
| Operating margin | -1143.71% | -8768.70% |
| Net margin | -1236.42% | -10567.18% |
| 52-week high | $14.34 | $3.40 |
| 52-week low | $0.50 | $0.12 |
| Distance from 52-week high | -96.05% | -92.33% |
| Average volume | 56.11K | 15.96M |
| Shares outstanding | 7.03M | 20.28M |
| Employees | 34 | 15 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Scilex is more profitable, keeping -1236.4 cents of every revenue dollar as net income versus -10567.2 cents for VivoSim Labs.
- VivoSim Labs grew revenue faster in its latest fiscal year (-9.03% vs -46.54%).
About Scilex
SCLX stock →Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 34 employees
About VivoSim Labs
VIVS stock →VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 15 employees
SCLX vs VIVS FAQ
Which is bigger, Scilex or VivoSim Labs?
VivoSim Labs (VIVS) is larger, with a market capitalization of $5.29M compared with $3.98M for Scilex (SCLX).
Are Scilex and VivoSim Labs in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.